AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7075121 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of naproxen daily
Number of subjects: 24
Study 7075121 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg of naproxen daily
Number of subjects: 24
Study 7075121 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (all doses)
Number of subjects: 24
Study 31582358 — intervention group
Group type: EXPERIMENTAL
Intervention: hIVIG (0.25 g/kg bodyweight, 500 mL infusion)
Number of subjects: 308
Study 31582358 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 308
Study 31582358 — intervention group
Group type: EXPERIMENTAL
Intervention: hIVIG
Number of subjects: 308
Study 31582358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 26280216 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural change from head up tilt (HUT) to supine position
Number of subjects: 15
Study 26280216 — intervention group
Group type: EXPERIMENTAL
Intervention: 30° passive leg raising (PLR)
Number of subjects: 15
Study 24019197 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) with spacer (AeroChamber Plus® with Flow‐Vu® Anti‐Static Valved Holding Chamber)
Number of subjects: 87
Study 24019197 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) without spacer
Number of subjects: 87
Study 24019197 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate/formoterol fumarate (MF/F) with spacer
Number of subjects: 87
Study 24019197 — intervention group
Group type: COMPARATOR
Intervention: F-Dry Powder Inhaler (F-DPI)
Number of subjects: 87
Study 23058047 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine (HF) 24 mg/kg (8 mg/kg every 6 h for 24 h)
Number of subjects: 194
Study 23058047 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine (HF) 72 mg/kg (8 mg/kg every 6 to 10 h for 3 days)
Number of subjects: 194
Study 23058047 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian analysis of patient data
Number of subjects: 194
Study 23058047 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (HF doses of 250, 500, and 1000 mg)
Number of subjects: 194
Study 19589010 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter or call
Number of subjects: 13057
Study 19589010 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter-call or call-letter
Number of subjects: 13057
Study 19589010 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter-call-letter
Number of subjects: 13057
Study 19589010 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 13057
Study 17301574 — intervention group
Group type: EXPERIMENTAL
Intervention: NYVAC expressing clade C gp120
Number of subjects: 0
Study 15247731 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional large bore nephrostomy drainage (20Fr)
Number of subjects: 30
Study 15247731 — intervention group
Group type: EXPERIMENTAL
Intervention: Small bore nephrostomy drainage (9Fr)
Number of subjects: 30
Study 15247731 — intervention group
Group type: COMPARATOR
Intervention: No nephrostomy drainage (tubeless)
Number of subjects: 30
Study 12539424 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-made denture adhesive paste
Number of subjects: 24
Study 12539424 — intervention group
Group type: COMPARATOR
Intervention: Fixodent denture adhesive paste
Number of subjects: 24
Study 10193451 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 10193451 — intervention group
Group type: COMPARATOR
Intervention: Other beta-blockers
Number of subjects: 0
Study 7713273 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes
Number of subjects: 120
Study 7713273 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes
Number of subjects: 120
Study 3234673 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (VS) IM 0.3 U/kg
Number of subjects: 34
Study 30568005 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 160
Study 30568005 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined AE and DASH diet
Number of subjects: 160
Study 30568005 — intervention group
Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 160
Study 30568005 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 160
Study 30568005 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater aerobic fitness
Number of subjects: 160
Study 30568005 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced CVD risk
Number of subjects: 160
Study 30568005 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced sodium intake
Number of subjects: 160
Study 28902127 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (forced treadmill exercise)
Number of subjects: 0
Study 28902127 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise group (control)
Number of subjects: 0
Study 25979318 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (aerobic and resistance training)
Number of subjects: 116
Study 25979318 — intervention group
Group type: COMPARATOR
Intervention: Healthy living control arm
Number of subjects: 116
Study 23708326 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA granules (Livact, 12 g/day) for 60 months
Number of subjects: 0
Study 23708326 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA treatment
Number of subjects: 0
Study 20684955 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg two times per day
Number of subjects: 43
Study 20684955 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg daily
Number of subjects: 43
Study 20684955 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 43
Study 20684955 — intervention group
Group type: COMPARATOR
Intervention: Healthy age‐ and body mass index‐matched women (control group)
Number of subjects: 43
Study 19212906 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ferrigluconate complex (SFGC)
Number of subjects: 59
Study 19212906 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-sucrose (IS)
Number of subjects: 59
Study 19212906 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight iron dextran (ID)
Number of subjects: 59
Study 17093110 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurvey letter
Number of subjects: 0
Study 15001611 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogens (114 mg of isoflavonoids)
Number of subjects: 55
Study 11337211 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic infection (properly completed reports)
Number of subjects: 308
Study 11337211 — intervention group
Group type: EXPERIMENTAL
Intervention: High psychological stress (properly completed reports)
Number of subjects: 308
Study 11337211 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic infection (improperly completed reports)
Number of subjects: 308
Study 11337211 — intervention group
Group type: EXPERIMENTAL
Intervention: High psychological stress (improperly completed reports)
Number of subjects: 308
Study 9041098 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (0.625 mg per day)
Number of subjects: 50
Study 9041098 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen + medroxyprogesterone acetate (2.5 mg daily)
Number of subjects: 50
Study 9041098 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol (0.1 mg per day)
Number of subjects: 50
Study 8327423 — intervention group
Group type: EXPERIMENTAL
Intervention: High-voltage pulsed galvanic stimulation (75 V, 10 Hz) applied to the back at spinal level T6
Number of subjects: 0
Study 8327423 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 3559814 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 41
Study 3559814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 2562269 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 1% sodium polyphosphate
Number of subjects: 148
Study 2562269 — intervention group
Group type: COMPARATOR
Intervention: Dentifrice A containing 5% sodium pyrophosphate
Number of subjects: 148
Study 2562269 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 148
Study 31984661 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily (n=213)
Number of subjects: 422
Study 31984661 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=209)
Number of subjects: 422
Study 30431378 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast weight loss method (calorie restriction, salt intake, walking, sexual self-restraint)
Number of subjects: 80
Study 30431378 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug treatment (vitamin E, orlistat, pioglitazone hydrochloride, atorvastatin, lisinopril, benzodiazepines, anti-inflammatory agents)
Number of subjects: 80
Study 27633647 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% cream
Number of subjects: 68
Study 27633647 — intervention group
Group type: COMPARATOR
Intervention: Topical clobetasol propionate 0.05% cream
Number of subjects: 68
Study 25346265 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal floor elevation technique (NF group)
Number of subjects: 14
Study 25346265 — intervention group
Group type: COMPARATOR
Intervention: Sinus lift technique (MS group)
Number of subjects: 14
Study 23581533 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac 100 mg b.i.d.
Number of subjects: 591
Study 23581533 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 50 mg t.i.d.
Number of subjects: 591
Study 21471283 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation
Number of subjects: 14
Study 19699868 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg, titrated to 50 mg daily
Number of subjects: 6632
Study 19699868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6632
Study 16243427 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 0
Study 16243427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15566510 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN 6 million units (MU) monotherapy (N=30)
Number of subjects: 120
Study 15566510 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with ribavirin and IFN 3 MU (N=30)
Number of subjects: 120
Study 15566510 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with ribavirin and IFN 6 MU (N=60)
Number of subjects: 120
Study 11423927 — intervention group
Group type: EXPERIMENTAL
Intervention: Oils high in linoleic acid (LA)
Number of subjects: 16
Study 11423927 — intervention group
Group type: EXPERIMENTAL
Intervention: Oils high in gamma-linolenic acid (GLA)
Number of subjects: 16
Study 11423927 — intervention group
Group type: COMPARATOR
Intervention: Oils high in oleic acid (OA)
Number of subjects: 16
Study 11423927 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h energy intake (EI) on the test day
Number of subjects: 16
Study 9238624 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA supplementation (3.4 g daily for 12 months)
Number of subjects: 20
Study 9238624 — intervention group
Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 20
Study 8473427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-short treatment protocol (buserelin administered on days 2, 3, and 4)
Number of subjects: 312
Study 8473427 — intervention group
Group type: COMPARATOR
Intervention: Long treatment protocol (buserelin administered from mid-luteal phase)
Number of subjects: 312
Study 2963838 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% nitrous oxide/70% oxygen
Number of subjects: 12
Study 2963838 — intervention group
Group type: COMPARATOR
Intervention: 30% room air/70% oxygen (control)
Number of subjects: 12
Study 29570536 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (Ex)
Number of subjects: 26
Study 29570536 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training with low-dose testosterone (ExT)
Number of subjects: 26
Study 29570536 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control (CONT)
Number of subjects: 26
Study 29570536 — intervention group
Group type: COMPARATOR
Intervention: All groups (including CONT)
Number of subjects: 26
Study 29570536 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (Ex) and Exercise training with low-dose testosterone (ExT)
Number of subjects: 26
Study 29570536 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in twist
Number of subjects: 26
Study 26942922 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut-consumption group
Number of subjects: 556
Study 26942922 — intervention group
Group type: COMPARATOR
Intervention: Peanut-avoidance group
Number of subjects: 556
Study 24735110 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatrician-led outreach service
Number of subjects: 116
Study 24735110 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 116
Study 21827579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyst aspiration together with tetracycline sclerotherapy (Group 1)
Number of subjects: 96
Study 21827579 — intervention group
Group type: COMPARATOR
Intervention: Only cyst aspiration without tetracycline sclerotherapy (Group 2)
Number of subjects: 96
Study 20581300 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiagent chemotherapy for Ewing's sarcoma
Number of subjects: 0
Study 20581300 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide excision for low-grade osteosarcomas
Number of subjects: 0
Study 20581300 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy for high-grade osteosarcoma
Number of subjects: 0
Study 20581300 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy for low-grade or periosteal sarcomas with high-grade disease
Number of subjects: 0
Study 20581300 — intervention group
Group type: EXPERIMENTAL
Intervention: RT followed by adjuvant chemotherapy for unresectable sarcomas
Number of subjects: 0
Study 20581300 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapy for relapsed or refractory disease
Number of subjects: 0
Study 20581300 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in clinical trials
Number of subjects: 0
Study 20581300 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiagent chemotherapy regimens for neoadjuvant and adjuvant treatment
Number of subjects: 0
Study 17210506 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined transcutaneous acupoint electrical stimulation (TAES) and electromagnetic millimeter wave (EMMW) therapy
Number of subjects: 47
Study 17210506 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 47
Study 15870545 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) at doses of 40, 80, and 160 microg/kg
Number of subjects: 32
Study 15870545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12444514 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular 20 mg of tenoxicam in 20 ml normal saline (Group T)
Number of subjects: 75
Study 12444514 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg bupivacaine in 20 ml normal saline (0.25%) (Group B)
Number of subjects: 75
Study 12444514 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular 20 mg of tenoxicam and 50 mg bupivacaine (0.25%) in 20 ml normal saline (Group BT)
Number of subjects: 75
Study 10636314 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric self-inflatable bag
Number of subjects: 80
Study 10636314 — intervention group
Group type: COMPARATOR
Intervention: Adult self-inflatable bag
Number of subjects: 80
Study 7677678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of fetal abdominal circumference
Number of subjects: 1135
Study 7677678 — intervention group
Group type: EXPERIMENTAL
Intervention: Symphysiofundal height measurement
Number of subjects: 1135
Study 7677678 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of symphysiofundal height and fetal abdominal circumference measurement
Number of subjects: 1135
Study 7677678 — intervention group
Group type: COMPARATOR
Intervention: Amniotic fluid index
Number of subjects: 1135
Study 2188449 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered acetylsalicylic acid (Aspalox = 325 mg ASS plus 300 mg magnesium aluminium hydroxide) daily
Number of subjects: 12
Study 2188449 — intervention group
Group type: EXPERIMENTAL
Intervention: Unbuffered acetylsalicylic acid (325 mg) daily
Number of subjects: 12
Study 7015492 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleat eye drops
Number of subjects: 7
Study 7015492 — intervention group
Group type: COMPARATOR
Intervention: 3% carbachol ophthalmic solution
Number of subjects: 7
Study 31486369 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy
Number of subjects: 0
Study 31486369 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study 30368324 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional stretching exercises (thrice a week for four weeks)
Number of subjects: 30
Study 30368324 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 26968796 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic release of IFS
Number of subjects: 23
Study 26968796 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 23
Study 24844853 — intervention group
Group type: EXPERIMENTAL
Intervention: New fenofibrate tablet formulation (145 mg)
Number of subjects: 15
Study 24844853 — intervention group
Group type: COMPARATOR
Intervention: Marketed fenofibrate tablet formulation (145 mg)
Number of subjects: 15
Study 21769566 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan (N=20)
Number of subjects: 41
Study 21769566 — intervention group
Group type: COMPARATOR
Intervention: No Tryptophan (N=21)
Number of subjects: 41
Study 18946704 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound-guided transbronchial needle aspiration
Number of subjects: 48
Study 17618750 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated courses of antenatal steroids
Number of subjects: 86
Study 17618750 — intervention group
Group type: COMPARATOR
Intervention: Single course of antenatal steroids
Number of subjects: 86
Study 14770034 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 16
Study 14770034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11253316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-benefit precuing paradigm (verbal precues for 300 pitches, 75% valid, 25% invalid)
Number of subjects: 20
Study 11253316 — intervention group
Group type: COMPARATOR
Intervention: No precuing (control condition)
Number of subjects: 20
Study 9681586 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg (FNZ2N)
Number of subjects: 6
Study 8595650 — intervention group
Group type: EXPERIMENTAL
Intervention: KP model (20 pharmacies)
Number of subjects: 600
Study 8595650 — intervention group
Group type: EXPERIMENTAL
Intervention: State model (67 pharmacies)
Number of subjects: 600
Study 8595650 — intervention group
Group type: COMPARATOR
Intervention: Control model (20 pharmacies)
Number of subjects: 600
Study 2698505 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (regular stand-ups initiated on days 1-2 after admission, continued for 1-2 weeks)
Number of subjects: 71
Study 2698505 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 71
Study 1105240 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg SAMe intravenously twice a day for 14 days
Number of subjects: 90
Study 1105240 — intervention group
Group type: COMPARATOR
Intervention: SAMe
Number of subjects: 90
Study 31780225 — intervention group
Group type: COMPARATOR
Intervention: 0% SBP
Number of subjects: 200
Study 31780225 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% SBP
Number of subjects: 200
Study 31780225 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% SBP
Number of subjects: 200
Study 31780225 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% SBP
Number of subjects: 200
Study 30884073 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES with short stimulation period
Number of subjects: 53
Study 30884073 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES with long stimulation period
Number of subjects: 53
Study 28068158 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-led follow-up program with standardized education and access to self-referral to an assigned project nurse
Number of subjects: 0
Study 28068158 — intervention group
Group type: COMPARATOR
Intervention: Current follow-up program with routine medicals
Number of subjects: 0
Study 25173079 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐Administered Interview (SAI)
Number of subjects: 85
Study 25173079 — intervention group
Group type: COMPARATOR
Intervention: Control condition (filler task)
Number of subjects: 85
Study 22418764 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concentration of heparin (LCH) 2,500 IU/ml
Number of subjects: 75
Study 22418764 — intervention group
Group type: COMPARATOR
Intervention: High concentration of heparin (HCH) 5,000 IU/ml
Number of subjects: 75
Study 21669369 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nailing
Number of subjects: 235
Study 21669369 — intervention group
Group type: COMPARATOR
Intervention: Unreamed intramedullary nailing
Number of subjects: 235
Study 19327618 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV1/SERCA2a (intracoronary infusion, doses ranging from 1.4 x 10(11) to 3 x 10(12) DNase resistant particles per patient)
Number of subjects: 9
Study 19327618 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 9
Study 16751032 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractive correction alone
Number of subjects: 84
Study 16751032 — intervention group
Group type: COMPARATOR
Intervention: Control group from a subsequent randomized trial
Number of subjects: 84
Study 14962728 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives for over 3 years
Number of subjects: 267400
Study 14962728 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestational injections during pregnancy
Number of subjects: 267400